Previous 10 | Next 10 |
MacroGenics press release (NASDAQ:MGNX): FY GAAP EPS of -$3.37 misses by $0.10. Revenue of $77.45M (-26.2% Y/Y) misses by $6.13M. For further details see: MacroGenics GAAP EPS of -$3.37 misses by $0.10, revenue of $77.45M misses by $6.13M
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumab Presented encouraging preclinical...
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Biotechnology company, Synaffix B.V. enters into a technology agreement with MacroGenics (NASDAQ:MGNX) to gain access to Synaffix's clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads, each designed to ...
I-Mab (NASDAQ:IMAB) announces that the Center for Drug Evaluation (NYSE:CDE) of China has approved its Investigational New Drug (IND) submission for the initiation of a phase 2 trial in China for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda) in patients with...
The following slide deck was published by MacroGenics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: MacroGenics, Inc. 2021 Q3 - Results - Earnings Call Presentation
MacroGenics, Inc. (MGNX) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Chris James - Vice President of Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call...
Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2021 Earnings Call Nov 02, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2021 Earnings Call Transcript
MacroGenics (NASDAQ:MGNX): Q3 GAAP EPS of -$0.86 misses by $0.19. Revenue of $15.66M (-14.2% Y/Y) misses by $18.78M. Press Release For further details see: MacroGenics EPS misses by $0.19, misses on revenue
Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug subst...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...